65,437 trials
Advanced Malignancies · Metastatic Cancer
Primary: Number of Participants With Treatment-related Adverse Events — 4; 4; 21; 17 Participants
Urinary Incontinence
Primary: Change From Study Baseline in the Daily Normalized Daytime Average Number of Urinary Incontinence Episodes in Treatment Cycle 1 — 2.66; 2.97; 3.99; -1.19 urinary…
Lower Urinary Tract Symptoms
Primary: Lactobacillus Safety — .594 Adverse Events — p==0.219
Visual Acuity
Primary: Microsphere Clearance Rate — 96.9; 98.1; 99.4; 96.6 percent clearance
Schizophrenia
Primary: Emax D1 Dopamine — 81.9 percentage
Cholelithiasis · Cholecystitis · Pancreatitis Biliary
Primary: Operative Time — 51.6; 44.4 minutes
Urinary Bladder Cancer · Bladder Cancer · Bladder Neoplasms
Primary: Treatment Schedule A: 12-Week Efficacy, Treatment Schedule B: 13-Week Efficacy — 40.9; 39.1 percentage of patients
Alzheimer's Disease
Primary: The Annual National Total Socioeconomic Cost for All AD Patients in China — 167.74 billion US$
Overweight · Obesity · Depression
Primary: Change of Body Mass Index (BMI) Z-score for Toddlers — 0.49; 0.50; 0.62; 0.52 z-score — p=0.555
Advanced Soft Tissue Sarcoma
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 3; 1; 22 Participants
Tonsillectomy
Primary: Intra-operative Blood Loss — 1.7 mL
Metastatic Leiomyosarcoma · Unresectable Leiomyosarcoma · Uterine Corpus Leiomyosarcoma
Primary: Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Among Patients With Advanced Leiomyosarcoma of the Uterus (ULMS) Treated With Nivolumab…
Dry Eye Syndromes
Primary: Tear Evaporation Rate — 77.7; 67; 75.3 g/m^2*h
Pain, Acute
Primary: Total Local Anesthetic Utilized in First 24 Hours — 126; 123 mg — p=0.74
Sleep Apnea, Central · Sleep Apnea, Obstructive
Primary: Assessment of the Apnoea-Hypopnea-Index (Number of Apneas (All Apneas, Obstructive, Mixed, Central) and Number of Hypopneas) Between ApneaLink Plus and a PSG System…